<DOC>
	<DOCNO>NCT02829307</DOCNO>
	<brief_summary>GSK3128349 small protein molecule ( biopharmaceutical ) bind albumin body , , pharmacological action . A pharmacologically active drug attach GSK3128349 goal change distribution and/or duration action attach drug . This study determine distribution pharmacokinetics ( duration ) GSK3128349 single intravenous infusion . GSK3128349 label radioisotope 89Zirconium allow visualized organ body use PET scanner multiple time point GSK3128349 dosing . The data study help predict distribution future drug attach GSK3128349 . The total duration subject 's participation approximately 10 week , include screening period .</brief_summary>
	<brief_title>A Positron Emission Tomography ( PET ) Imaging Study Investigate Biodistribution Clearance Albumin Binding Domain Antibody ( AlbudAb ) GSK3128349 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5x Upper Limit Normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) . Body Mass Index ( BMI ) within range 19.0 31.0 kilogram ( kg ) /meter ( m^2 ) ( inclusive ) . Subjects must agree use one contraception method list protocol . Capable give write informed consent , include compliance study requirement restriction . Average Corrected QT interval ( QTc ) &lt; =450 millisecond ( msec ) Current evidence history influenzalike illness . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History , current , acute renal failure , know renal disease , renal disorder abnormality may compromise renal function . This include one kidney . Previous inclusion research and/or medical protocol involve nuclear medicine , PET radiological investigation occupational exposure , together propose study , result total radiation exposure great 10 mSv 3 year period . Clinical exposure subject receives direct benefit ( example , diagnostic test ) include calculation . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit . One unit equivalent 8 g alcohol : halfpint ( ~240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Unable refrain use prescription drug within 7 day 5 halflives ( whichever longer ) prior first dose study treatment , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Subject smoker &gt; =5 cigarettes/day smoke history &gt; 5 pack year History sensitivity study treatment component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Subject suffers claustrophobia limit ability remain still PET/CT scanner require amount time . Subject metal present body interfere PET/CT scanning . Estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m^2 ( utilizing Chronic Kidney Disease Epidemiology Collaboration ( CKIEPI ) equation ) . Urine mg protein/mg creatinine Urine Protein Creatinine Ratio ( UPCR ) &gt; 0.3 . Evidence hematuria urinalysis ( 1plus great dipstick test ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C ( Hep C ) antibody result within 3 month screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . A positive prestudy drug/alcohol screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>89Zirconium</keyword>
	<keyword>Open label</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Radioactive</keyword>
	<keyword>Clearance</keyword>
	<keyword>Biodistribution</keyword>
</DOC>